Difference between revisions of "Profiles"

From QIBA Wiki
Jump to navigation Jump to search
m
 
(219 intermediate revisions by 6 users not shown)
Line 1: Line 1:
 
__NOTOC__
 
__NOTOC__
Profiles published here have completed one of the '''[[QIBA Profile Stages]]''' of development and been approved by their [[Committees|Biomarker Committee]].
+
Profiles published here have completed one of the '''[[QIBA Profile Stages]]''' of development and been approved by their [[Committees|Biomarker Committee]].
  
===[[QIBA_Profile_Stages#Stage_3:_Technically_Confirmed|Stage 3]]: Technically Confirmed Profiles===
+
Profiles '''[[How to use QIBA Profiles|may be of use]]''' at any Stage.
* [[Media:QIBA_FDG-PET_Profile_v113.pdf|FDG-PET/CT for Response to Cancer Therapy 2016-11-18]]
 
:* [[Media:UPICT Oncologic FDG-PETCTProtocol Dec-2014a.pdf|UPICT Protocol - Oncology FDG-PET CT v2.0 Dec-2014]]
 
  
 +
===[[QIBA_Profile_Stages#Stage_3:_Technically_Confirmed|Stage 3]]: Clinically Feasible (formerly Technically Confirmed) Profiles===
 +
 +
 +
*[[Media:Supplement QIBA AmyloidPET 3Jun2022 TechnicallyConfirmed.pdf| PET Amyloid 2022-06-03]]
 +
 +
*[[Media:MRE-QIBAProfile-2022-02-14-TECHNICALLY-CONFIRMED.pdf| MR Elastography of the Liver 2022-02-14]]
 +
 +
* [[Media:QIBA CT Vol SmallLungNoduleAssessmentInCTScreening 2018.11.18-clean-4.pdf|CT Small Lung Nodule Volume Assessment and Monitoring in Low Dose Screening 2018-11-18]]
 +
 +
* [[Media:QIBACTVol TumorVolumeChange(2022)-20220721.pdf|CT Tumor Volume Change for Advanced Disease (CTV-AD) 2022-07-21 Streamlined Profile]]
 +
:* 32 pages including Conformance Checklists
 +
 +
* [[Media:QIBA FDG-PET Profile v113.pdf|FDG-PET/CT for Response to Cancer Therapy 2016-11-18]]
 +
:*[[Media:UPICT Oncologic FDG-PETCTProtocol Dec-2014a.pdf|UPICT Protocol - Oncology FDG-PET CT v2.0 2014-12]]
  
 
===[[QIBA_Profile_Stages#Stage_2:_Consensus|Stage 2]]: Consensus Profiles===
 
===[[QIBA_Profile_Stages#Stage_2:_Consensus|Stage 2]]: Consensus Profiles===
*[[Media:001.QIBA_SPECT_Ioflupane Profile.v1.1 post-public comments.clean copy.2017 06 26.pdf | SPECT Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease v1.1 2017-06-26]]  
+
 
 +
*[[Media:QIBA CTA Profile as of 2020-Mar-10.pdf| CTA Atherosclerosis 2020-03-10]]
 +
:*[[Media:QIBA CTA Field Test Checklist.xlsx| CTA Atherosclerosis Checklist 2020-05-28]]
 +
 
 +
*[[Media:QIBA CT Lung Density Profile 090420-clean.pdf| CT Lung Density Profile_09.04.2020, clean version]] (Contains Conformance Checklist, Appendix B) 2020-10-23
 +
:*[[Media:QIBA CT Lung Density Protocols-Appendix E.xlsx|Appendix E:CT Lung Density Protocols 2019-06-26]]
 +
 
 +
*[[Media:DCE-MRI Quantification Profile v1.0.pdf| MR DCE Quantification v1.0 2012-08-08]]
 +
 
 +
*[[Media:QIBA DWIProfile Consensus Dec2019 Final.pdf| MR Diffusion-Weighted Imaging (DWI) 2019-12-20]]
 +
 
 +
*[[Media:QIBA DSC-MRI Stage2-Consensus Profile.pdf| MR Dynamic Contrast Susceptibility (DSC) 2020-10-22]]
 +
 
 +
*[[Media:MRE-QIBAProfile-2018-05-02-CONSENSUS.pdf| MR Elastography of the Liver 2018-05-02]]
 +
 
 +
*[[Media:QIBA Profile MSK-Cartilage-Stage2 Profile.pdf| MR MSK cartilage for joint disease 2021-09-25]]
 +
 
 +
*[[Media:001.QIBA SPECT Ioflupane Profile.v1.1 post-public comments.clean copy.2017 06 26.pdf| SPECT Ioflupane for Neurodegenerative Disease v1.1, 2017-06-26]]
 +
 
 +
*[[Media:002.QIBA SPECT Ioflupane Profile v2.0.2019 10 15.pdf| SPECT Ioflupane for Neurodegenerative Disease v2.0, 2019-10-15]]
 
:*[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|Checklist - SPECT Profile Conformance]]
 
:*[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|Checklist - SPECT Profile Conformance]]
  
* [[Media:QIBA_CTVol_TumorVolumeChangeProfile_Consensus-20161121b.pdf| CT Tumor Volumetry for Advanced Disease 2016-11-21b]]  
+
*[[Media:QIBA SPECT 99mTC Profile 10.21.19.pdf|SPECT-CT: Estimating the Concentration of 99mTc Based Imaging Biomarkers in Large and Small Volumes of Interest Profile 2019-10-21]]
:* [[Media:QIBA_CVol_TumorVolumeChangeChecklist-20161205_-_Field_Test_version_1.0.docx| Checklist - CT Tumor Volumetry for Advanced Disease]]
+
 
 +
*[[Media:QIBA US SWS Profile 04.25.2022-clean version.pdf|US Shear Wave Speed for Liver Fibrosis-2022-04-25]] ('''closed''' on May 3, 2022)
 +
:*[[Media:SWS Checklists-Appendix E-04.25.2022.xlsx|Appendix E: SWS Checklists]] (updated April 25, 2022)
 +
 
 +
===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 1]]: Public Comment Profiles ===
 +
 
 +
'''Please submit comments using the '''[https://forms.gle/bPzUAuLKJnHYGbVS7 '''online form''']
 +
 
 +
*[[Media:QIBA DCE-MRI Profile-Stage 1-Public Comment.pdf|MR DCE-MRI Quantification (DCEMRI-Q) 2020-10-12]] ('''closed''' on March 10, 2021)
 +
 
 +
*[[Media:QIBA Profile MSK-Cartilage-Stage1 Profile.pdf|MR MSK cartilage for joint disease 2020-05-18]] ('''closed''' on October 29, 2020)
  
*[[Media:QIBA_CT_Vol_LungNoduleAssessmentInCTScreening_v5-2-16b.docx|QIBA Lung Nodule Volume Assessment and Monitoring in Low Dose CT Screening Profile 2016-06-01]] (''Closed Sept 2016'')
+
*[[Media:QIBA fMRI Profile 1 PC-rev1.pdf| fMRI for Sensorimotor Mapping 2017-06-19]] ('''closed''' on December 31, 2017)
:*[[Media:QIBA Small Nodule Profile References - Accuracy.xlsx|Spreadsheet: Small Nodule Profile References - Accuracy]]
 
:*[[Media:QIBA Small Nodule Profile References - Precision.xlsx|Spreadsheet: Small Nodule Profile References - Precision]]
 
  
===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 1]]: Public Comment Profiles===
 
''--There are currently no Profiles open for Public Comment--''
 
  
'''Please submit all public comments through the following online form: http://tinyurl.com/QIBA-Public-Comment-Form
+
'''[[Comment Resolutions]]''' <font color="black">are posted for '''Past Public Comments''' and '''Past Technical Confirmations'''.
<br /><font size="2" color="FireBrick">(Note: each form accommodates 10 comments; you may submit additional forms as necessary)</font>'''
 
  
  
Public Comment closed for the following Profiles (comment resolution is currently underway):
+
====Format for Citing Profiles====
*[[Media:QIBA_fMRI_Profile_1_PC-rev1.pdf| QIBA fMRI Profile 2017-06-19]] (''Closed on December 31, 2017'')
+
Cite QIBA Profile documents as:
*[[Media:QIBA_AmyloidPET_15June2017.pdf| QIBA PET Amyloid Profile 2017-06-15]] (''Closed on September 15, 2017'')
 
*[[Media:Draft-MRE-QIBAProfile-2017-07-28_clean.pdf| QIBA MRE Profile 2017-08-15]] (''Closed on September 15, 2017'')
 
*[[Media:QIBADWIProfilev1.45_20170427_v5_accepted_linenumbers.pdf| DWI Profile 2017-04-27]] (''Closed on August 25, 2017'')
 
  
==Format for Citing Profiles==
+
:''Specific QIBA Biomarker Committee. Specific Profile Title'', Quantitative Imaging Biomarkers Alliance. ''Version. Profile Stage''. ''Date''. Available from: ''URL''
<br /><font size="2" color="FireBrick">'''Note to users:'''</font>  When referencing QIBA Profile documents, ''please use the following format'':
 
  
Specific QIBA Biomarker Committee. * Specific Profile Title, * Quantitative Imaging Biomarkers Alliance. * Version. * Profile Stage. * QIBA, * Date. * Available from: URL
+
Example:
  
'''Format example:'''
+
:QIBA MR Biomarker Committee. MR Elastography of the Liver, Quantitative Imaging Biomarkers Alliance. Profile Stage: Consensus. June 6, 2019. Available from: http://qibawiki.rsna.org/index.php/Profiles
  
QIBA SPECT Biomarker Committee.  Quantifying Dopamine Transporters with 123Iodine Labeled Ioflupane in Neurodegenerative Diseases, Quantitative Imaging Biomarkers Alliance.  Version 1.1.  Profile Stage: Consensus.  QIBA, June 30, 2017.  Available from: 
 
http://qibawiki.rsna.org/index.php/Profiles
 
  
==Statements of Endorsement==
+
====Statements of Endorsement====
 
*[[Industry]]
 
*[[Industry]]
 
*[[Clinical Sites]]
 
*[[Clinical Sites]]
Line 47: Line 77:
  
  
==See Also==
+
==== See Also====
 
*[[How to use QIBA Profiles]]
 
*[[How to use QIBA Profiles]]
 
*[[Committees|Biomarker Committee]] pages may also have links to DRAFT Profile documents for the next Stage.
 
*[[Committees|Biomarker Committee]] pages may also have links to DRAFT Profile documents for the next Stage.

Latest revision as of 14:14, 21 July 2022

Profiles published here have completed one of the QIBA Profile Stages of development and been approved by their Biomarker Committee.

Profiles may be of use at any Stage.

Stage 3: Clinically Feasible (formerly Technically Confirmed) Profiles

  • 32 pages including Conformance Checklists

Stage 2: Consensus Profiles

Stage 1: Public Comment Profiles

Please submit comments using the online form


Comment Resolutions are posted for Past Public Comments and Past Technical Confirmations.


Format for Citing Profiles

Cite QIBA Profile documents as:

Specific QIBA Biomarker Committee. Specific Profile Title, Quantitative Imaging Biomarkers Alliance. Version. Profile Stage. Date. Available from: URL

Example:

QIBA MR Biomarker Committee. MR Elastography of the Liver, Quantitative Imaging Biomarkers Alliance. Profile Stage: Consensus. June 6, 2019. Available from: http://qibawiki.rsna.org/index.php/Profiles


Statements of Endorsement


See Also